INTRODUCTION: Millions of U.S. patients have been hospitalized for coronavirus disease 2019 (COVID-19). After discharge, these patients often have extensive health care needs, but out-of-pocket burden for this care is poorly described. Using national data, we assessed out-of-pocket spending during the 90 days after COVID-19 hospitalization among privately insured and Medicare Advantage patients. METHODS: In May 2021, we conducted a cross-sectional analysis of the IQVIA PharMetrics Plus for Academics Database, a national de-identified claims database. Among privately insured and Medicare Advantage patients hospitalized for COVID-19 between March-June 2020, we calculated mean out-of-pocket spending for care within 90 days of discharge. To contextualize results, we repeated analyses for patients hospitalized for bacterial pneumonia. RESULTS: Among 1,465 COVID-19 patients included, 516 (35.2%) and 949 (64.8%) were covered by private insurance and Medicare Advantage plans. Among these patients, mean (SD) post-discharge out-of-pocket spending was $534 (1,045) and $680 (1,360); spending exceeded $2,000 for 7.0% and 10.3%. Compared with patients with pneumonia, mean post-discharge out-of-pocket spending among COVID-19 patients was higher among the privately insured ($534 vs $445) and lower among Medicare Advantage patients ($680 vs $918). CONCLUSIONS: Out-of-pocket spending for immediate post-discharge care can be substantial for many patients hospitalized for COVID-19. Among Medicare Advantage patients, post-discharge out-of-pocket spending was higher after pneumonia hospitalizations, potentially because insurer cost-sharing waivers fully covered the costs of COVID-19-related readmissions during the study period. As many insurers allowed such waivers to expire in 2021, it is important to repeat analyses among patients more recently hospitalized for COVID-19.
Understanding the evolution of SARS-CoV-2 virus in various regions of the world during the Covid19 pandemic is essential to help mitigate the effects of this devastating disease. We describe the phylogenomic and population genetic patterns of the virus in Mexico during the pre-vaccination stage, including asymptomatic carriers. A RT-qPCR screening and phylogenomics reconstructions directed a sequence/structure analysis of the Spike glycoprotein, revealing mutation of concern E484K in genomes from central Mexico, in addition to the nationwide prevalence of the imported variant 20C/S:452R (B.1.427/9). Overall, the detected variants in Mexico show Spike protein mutations in the N-terminal domain (i.e., R190M), in the receptor-binding motif (i.e., T478K, E484K), within the S1-S2 subdomains (i.e., P681R/H, T732A), and at the basis of the protein, V1176F, raising concerns about the lack of phenotypic and clinical data available for the variants of interest (VOI) we postulate: 20B/478K.V1 (B.1.1.222 or B.1.1.519) and 20B/P.4 (B.1.1.28.4). Moreover, the population patterns of Single Nucleotide Variants (SNVs) from symptomatic and asymptomatic carriers obtained with a self-sampling scheme confirmed the presence of several fixed variants, and differences in allelic frequencies among localities. We identified the mutation N:S194L of the Nucleocapsid protein associated with symptomatic patients. Phylogenetically, this mutation is frequent in Mexican sub-clades, so we propose an additional VOI, 20A/N:194L.V2 (B.1.243). Our results highlight the dual and complementary role of Spike and Nucleocapsid proteins in adaptive evolution of SARS-CoV-2 to their hosts and provide a baseline for specific follow-up of mutations of concern during the vaccination stage.
Background: Clinical and virologic characteristics of COVID-19 infections in veterans in New England have not been described. Objectives: To evaluate clinical and virologic factors impacting COVID-19 outcomes. Study Design: We reviewed charts and sequenced virus from nasopharyngeal specimens with confirmed SARS-CoV-2 from 426 veterans in six New England states between April and September, 2020. Peak disease severity, hospitalization, and mortality were correlated to clinical, demographic, and virologic factors. Results: Of 426 veterans, 274 had complete and accessible charts. 92.7% were men, 83.2% White, with mean age 63 years. On multivariate regression, significant predictors of hospitalization were age (OR: 1.05) and non-white race (OR: 2.39). Mortality and peak disease severity varied by age (OR 1.06 and 1.07 respectively) and oxygen requirement on admission (OR6.74 and 45.7). Dementia (OR: 3.44) was also associated with mortality. Most (97.3%) of our samples were dominated by the spike protein D614G substitution, and were from SARS-CoV-2 B.1 lineage or one of 37 different B.1 sub-lineages, with none representing more than 8.7% of the cases. Conclusions: In an older cohort of veterans from the six New England states with a high comorbidity burden, age was the largest predictor of hospitalization, peak disease severity, and mortality. Non-white veterans were more likely to be hospitalized, and patients who required oxygen on admission were more likely to have severe disease and higher rates of mortality. Multiple SARS-CoV-2 lineages were distributed in patients in New England early in the COVID-19 era, mostly related to viruses from New York with D614G mutation.
To respond to pandemics such as COVID-19, policy makers have relied on interventions that target specific age groups or activities. Such targeting is potentially contentious, so rigorously quantifying its benefits and downsides is critical for designing effective and equitable pandemic control policies. We propose a flexible modeling framework and algorithms to compute optimally targeted interventions that coordinate across two dimensions of heterogeneity: age of different groups and the specific activities that individuals engage in during the course of a day. We showcase a complete implementation in a case study focused on the COVID-19 epidemic in the Île-de-France region of France, based on hospitalization, community mobility, social contacts and economic data. We find that optimized dual-targeted policies generate substantial complementarities that lead to Pareto improvements, reducing the number of deaths and the economic losses overall and reducing the time in confinement for each age group, compared to less targeted interventions. These policies have a simple and explainable structure. Since dual-targeted policies could lead to increased discrepancies in the confinements faced by distinct groups, we also quantify the impact of requirements that explicitly limit such disparities, and find that satisfactory trade-offs may be achievable through limited targeting.
The effective reproductive number Re is a key indicator of the growth of an epidemic. Since the SARS-CoV-2 pandemic started, many methods and online dashboards have sprung up to monitor this number. However, these methods are not always thoroughly tested or are applied only to a limited geographic range. Here, we present a method for near real time monitoring of Re, applied to epidemic data from 170 countries. We thoroughly validate the method on simulated data, and present an intuitive web interface for interactive data exploration. We show that in the majority of countries the estimated Re dropped below 1 only after the introduction of major non-pharmaceutical interventions. For Europe, Asia, and North America we found that the implementation of non-pharmaceutical interventions was associated with reductions in the effective reproductive number. Globally, we found that relaxing non-pharmaceutical interventions did not fully revert Re values to their original levels. Generally, our framework is useful both to inform governments and the general public on the status of the epidemic in their country, as well as a source for detailed comparison between countries and in relation to local public health policies and external covariates such as mobility, behavioural, or weather data.
Ivermectin Treatment Efficacy in Covid-19 High Risk Patients - Condition: COVID-19
Intervention: Drug: Ivermectin 0.4mg/kg/day for 5 days
Sponsor: Clinical Research Centre, Malaysia
Not yet recruiting
To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants - Condition: Covid19
Intervention: Drug: Black Seed Oil Cap/Tab
Sponsor: Novatek Pharmaceuticals
Recruiting
Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19 - Condition: COVID-19
Interventions: Drug: XAV-19; Drug: Placebo
Sponsor: Xenothera SAS
Recruiting
Intramuscular VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19 - Condition: Covid19
Intervention: Biological: VIR-7831
Sponsors: Vir Biotechnology, Inc.; GlaxoSmithKline
Not yet recruiting
Clinical Trial With N-acetylcysteine and Bromhexine for COVID-19 - Condition: COVID-19
Interventions: Drug: Vitamin C; Drug: N-acetylcysteine (NAC); Drug: NAC + Bromhexine (BMX)
Sponsors: Universidade Federal do Ceara; Paulista School of Medicine-EPM, UNIFESP; Health Surveillance Secretariat - SVS; Central Laboratory of Public Health of Ceara - LACEN-CE; Leonardo da Vinci Hospital - HLV; São José Hospital for Infectious Diseases - HSJ; Ceará Health Secretariat - SESA; Municipal Health Secretary - SMS-Fortaleza
Not yet recruiting
Augmentation of Immune Response to COVID-19 mRNA Vaccination Through OMT With Lymphatic Pumps - Condition: Covid19
Intervention: Other: Osteopathic Manipulative Treatment (OMT)
Sponsors: Western University of Health Sciences; American College of Osteopathic Physicians; American Osteopathic Foundation; Osteopathic Physicians and Surgeons of California; Xavier-Nichols Foundation
Recruiting
Nervous System Symptoms Associated With COVID 19 - Condition: Covid19
Interventions: Other: NEURO +; Other: NEURO -
Sponsor: University Hospital, Toulouse
Completed
Open Label, Single-Center Study Utilizing BIOZEK COVID-19 Antigen Rapid Test - Condition: Covid-19 Testing
Intervention: Diagnostic Test: Biozek Covid-19 Antigen Rapid Test (Saliva)
Sponsor: Mach-E B.V.
Recruiting
The Burden of COVID-19 Survivorship - Condition: Covid19
Intervention: Other: Exercise Training
Sponsor: Mayo Clinic
Not yet recruiting
Community-based Post-exposure Prophylaxis for COVID-19 - Condition: Covid19
Interventions: Other: Guduchi Ghanvati; Other: Standard guidelines
Sponsors: NMP Medical Research Institute; Aarogyam UK; Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University; Samta Ayurveda Prakoshtha, India; Padmanabhama Ayurveda Hospital and Research Centre
Completed
Vitamin A Supplementation in Children With Moderate to Severe Covid-19 - Condition: Covid19
Intervention: Dietary Supplement: Vitamin A supplement
Sponsor: Shiraz University of Medical Sciences
Not yet recruiting
Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19 - Condition: Covid19
Interventions: Drug: Favipiravir; Drug: Nitazoxanide; Other: Nitazoxanide Placebo
Sponsors: Coordinación de Investigación en Salud, Mexico; University College, London; Centro de Investigacion y Estudios Avanzados del Instituto Politecnico Nacional (CINVESTAV); Universidad Autonoma de Guadalajara; Siegfried Rhein S.A. de C.V.; Strides Pharma Science Limited; Hakken Enterprise
Not yet recruiting
Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients - Condition: Covid19
Interventions: Biological: Dupilumab; Drug: Placebo
Sponsors: University of Virginia; PBM C19 Research, LLC (PBM); Virginia Catalyst, Virginia Biosciences Health Research Corporation (VBHRC)
Recruiting
Impact of Moderate Exercise Training on Vitals and Peak VO2 in Different Age Categories of Adult in COVID-19. - Condition: Covid19
Interventions: Other: Moderate Exercise Training (Age Group 1; Young adult 17 -30 years); Other: Moderate Exercise Training (Age Group 2; 31 to 45 years); Other: Moderate Exercise Training (Age Group 3; Above 45 years)
Sponsor: Riphah International University
Recruiting
Infliximab in the Treatment of Patients With Severe COVID-19 Disease - Condition: COVID-19
Interventions: Drug: Infliximab; Other: Standard of Care
Sponsors: Jena University Hospital; German Federal Ministry of Education and Research; Celltrion
Not yet recruiting
An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants - The SARS-CoV-2 variants replacing the first wave strain pose an increased threat by their potential ability to escape pre-existing humoral protection. An angiotensin converting enzyme 2 (ACE2) decoy that competes with endogenous ACE2 for binding of the SARS-CoV-2 spike receptor binding domain (S RBD) and inhibits infection may offer a therapeutic option with sustained efficacy against variants. Here, we used Molecular Dynamics (MD) simulation to predict ACE2 sequence substitutions that might…
Melatonin and other indoles show antiviral activities against swine Coronaviruses in vitro at pharmacological concentrations - The current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), highlights major gaps in our knowledge on the prevention control and cross-species transmission mechanisms of animal coronaviruses. Transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), and porcine delta-coronavirus (PDCoV) are three common swine coronaviruses and have similar clinical features. In absence of effective treatments, they…
Manipulation of the unfolded protein response: A pharmacological strategy against coronavirus infection - Coronavirus infection induces the unfolded protein response (UPR), a cellular signalling pathway composed of three branches, triggered by unfolded proteins in the endoplasmic reticulum (ER) due to high ER load. We have used RNA sequencing and ribosome profiling to investigate holistically the transcriptional and translational response to cellular infection by murine hepatitis virus (MHV), often used as a model for the Betacoronavirus genus to which the recently emerged SARS-CoV-2 also belongs….
Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions - In the pursuit of suitable and effective solutions to SARS-CoV-2 infection, we investigated the efficacy of several phenolic compounds in controlling key cellular mechanisms involved in its infectivity. The way the SARS-CoV-2 virus infects the cell is a complex process and comprises four main stages: attachment to the cognate receptor, cellular entry, replication and cellular egress. Since, this is a multi-part process, it creates many opportunities to develop effective interventions. Targeting…
Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia - COVID-19 (coronavirus disease 2019) represents a pandemic, and several vaccines have been produced to prevent infection and/or severe sequelae associated with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection. There have been several reports of infrequent post vaccine associated thrombotic events, in particular for adenovirus-based vaccines. These have variously been termed VIPIT (vaccine-induced prothrombotic immune thrombocytopenia), VITT (vaccine-induced [immune]…
An in vitro antiviral activity of iodine complexes against SARS-CoV-2 - Since the emergence of COVID-19 pandemic in China in late 2019, scientists are striving hard to explore non-toxic, viable anti-SARS-CoV-2 compounds or medicines. We determined In vitro anti-SARS-CoV-2 activity of oral formulations (syrup and capsule)of an Iodine-complex (Renessans). First, cell cytotoxicity of Renessans on the Vero cells was determined using MTT assay. Afterwards, the antiviral activity of Renessans was determined using viral inhibition assays and TCID(50). For this, nontoxic…
Correction to “Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir” - [This corrects the article DOI: 10.1021/acsptsci.1c00022.].
Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection - The 2019-2020 winter was marked by the emergence of a new coronavirus (SARS-CoV-2) related disease (COVID-19), which started in Wuhan, China. Its high human-to-human transmission ability led to a worldwide spread within few weeks and has caused substantial human loss. Mechanical antiviral control approach, drug repositioning, and use of COVID-19 convalescent plasmas (CPs) were the first line strategies utilized to mitigate the viral spread, yet insufficient. The urgent need to contain this…
Humoral Response after SARS-Cov-2 mRNA Vaccine in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients - Background Kidney transplant recipients and patients receiving hemodialysis are immunocompromised populations that are prioritized for COVID-19 vaccination but were excluded from clinical trials of SARS-CoV-2 mRNA vaccines. Antibody titers and rates of seroconversion following vaccination are lower among patients with chronic kidney disease and those taking immunosuppressants compared with controls. Data are lacking regarding their humoral response to vaccination to prevent COVID-19. Methods…
Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity - Infection by highly pathogenic coronaviruses results in substantial apoptosis. However, the physiological relevance of apoptosis in the pathogenesis of coronavirus infections is unknown. Here, with a combination of in vitro, ex vivo, and in vivo models, we demonstrated that protein kinase R-like endoplasmic reticulum kinase (PERK) signaling mediated the proapoptotic signals in Middle East respiratory syndrome coronavirus (MERS-CoV) infection, which converged in the intrinsic apoptosis pathway….
Higher Levels of Harsh Parenting During the COVID-19 Lockdown in the Netherlands - Previous studies on the impact of COVID-19 indicate that pandemic-related distress increases risks for child maltreatment, although data on the scope of this problem are still scarce. Here, we assessed whether parents with toddlers (n = 206) more often used harsh discipline during the lockdown in the Netherlands compared to a matched parent sample collected prior to the pandemic (n = 1,030). Parents were matched on background characteristics using propensity score matching. We found that harsh…
Humoral and cellular immune responses against SARS-CoV-2 variants and human coronaviruses after single BNT162b2 vaccination - CONCLUSION: These results call into question whether neutralizing antibodies significantly contribute to protection against COVID-19 upon single vaccination and suggest that cellular immunity is central for the early defenses against COVID-19.
Structural Basis and Function of the N Terminus of SARS-CoV-2 Nonstructural Protein 1 - Nonstructural protein 1 (Nsp1) of severe acute respiratory syndrome coronaviruses (SARS-CoVs) is an important pathogenic factor that inhibits host protein translation by means of its C terminus. However, its N-terminal function remains elusive. Here, we determined the crystal structure of the N terminus (amino acids [aa] 11 to 125) of SARS-CoV-2 Nsp1 at a 1.25-Å resolution. Further functional assays showed that the N terminus of SARS-CoVs Nsp1 alone loses the ability to colocalize with ribosomes…
alpha(V) beta(6) Integrin: An Intriguing Target for COVID-19 and Related Diseases - The outbreak of SARS-CoV-2 has been an extraordinary event that constituted a global health emergency. As the novel coronavirus is continuing to spread over the world, the need for therapeutic agents to control this pandemic is increasing. α(V) β(6) Integrin may be an intriguing target not only for the inhibition of SARS-CoV-2 entry, but also for the diagnosis/treatment of COVID-19 related fibrosis, an emerging type of fibrotic disease which will probably affect a significant part of the…
A comprehensive review of the therapeutic potential of curcumin nanoformulations - Today, due to the prevalence of various diseases such as the novel coronavirus (SARS-CoV-2), diabetes, central nervous system diseases, cancer, cardiovascular disorders, and so on, extensive studies have been conducted on therapeutic properties of natural and synthetic agents. A literature review on herbal medicine and commercial products in the global market showed that curcumin (Cur) has many therapeutic benefits compared to other natural ingredients. Despite the unique properties of Cur, its…
폐마스크 밀봉 회수기 - 본 발명은 마스크 착용 후 버려지는 일회용 폐마스크를 비닐봉지에 넣은 후 밀봉하여 배출함으로써, 2차 감염을 예방하고 일반 생활폐기물과 선별 분리 배출하여 환경오염을 방지하는 데 그 목적이 있다. - link
COST EFFECTIVE PORTABLE OXYGEN CONCENTRATOR FOR COVID-19 - - link
METHOD OF IDENTIFYING SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) RIBONUCLEIC ACID (RNA) - - link
Erweiterbare Desinfektionsvorrichtung, umfassend: einen Hauptkörper, der eine umgekehrt U-förmige Basisplatte aufweist, wobei die umgekehrt U-förmige Basisplatte mit einer Öffnung versehen ist und jeweils eine Seitenplatte sich von zwei Seiten der umgekehrt U-förmigen Basisplatte nach außen erstreckt; und mindestens eine Desinfektionslampe, die in den auf zwei Seiten des Hauptkörpers befindlichen Seitenplatten angeordnet ist und eine Lichtemissionseinheit, eine Erfassungseinheit, eine Steuereinheit und eine Stromversorgungseinheit umfasst.
Einfache Sterilisationsvorrichtung, mit einem Hauptkörper (11), der in Längsrichtung einen ersten Plattenabschnitt (111) und in Querrichtung einen zweiten Plattenabschnitt (112) aufweist, wobei der erste Plattenabschnitt (111) und der zweite Plattenabschnitt (112) L-förmig miteinander verbunden sind; und einer Sterilisationslampe (12), die an dem Hauptkörper (11) angeordnet ist und eine Lichtemissionseinheit (121), eine Sensoreinheit (122), eine Steuereinheit (123) und eine Stromeinheit (124) aufweist.
Klemmarme aufweisende Desinfektionsvorrichtung, umfassend: einen Hauptkörper; eine Desinfektionslampe, die im Hauptkörper angeordnet ist und eine Lichtemissionseinheit, eine Erfassungseinheit, eine Steuereinheit und eine Stromversorgungseinheit umfasst; einen Klemmabschnitt, der auf einer Seite des Hauptkörpers angeordnet ist, wobei der Klemmabschnitt zwei gegenüberliegende Greifbacken umfasst, wobei mindestens eine der beiden Greifbacken mit einer Schwenkachse versehen ist, wobei ein Klemmraum durch passgenaues Schließen der beiden Greifbacken entsteht und die beiden Greifbacken jeweils mit einem Durchgangsloch versehen sind; einen Befestigungsabschnitt, der durch die Durchgangslöcher der beiden Greifbacken hindurchgeführt ist;und ein Schild, das auf einer Seite des Klemmabschnitts angeordnet und mit einem Aufnahmeloch versehen ist.
Aufhängbare Sterilisationsvorrichtung, mit einem Hauptkörper (11); einer Sterilisationslampe (12), die an dem Hauptkörper (11) angeordnet ist und eine Lichtemissionseinheit (121), eine Sensoreinheit (122), eine Steuereinheit (123) und eine Stromeinheit (124) aufweist; einem Klemmabschnitt (13), der an einer Seite des Hautpkörpers (11) angeordnet ist und zwei gegenüberliegend angeordnete Klemmbacken (131) aufweist, wobei mindestens eine der beiden Klemmbacken (131) mit einem Achsbolzen (132) versehen ist, wobei die beiden Klemmbacken (131) beim Schließen einen Klemmraum (134) bilden, und wobei die beiden Klemmbacken (131) jeweils mit einem Durchgangsloch (135) versehen sind; und einem Befestigungselement (14), das durch die Durchgangslöcher (135) der beiden Klemmbacken (131) hindurchgeführt wird.
Sterilisationsvorrichtung zur Verbesserung der Desinfektionswirkung, umfassend: einen Hauptkörper, der eine erste Oberfläche, eine von der ersten Oberfläche abgewandte zweite Oberfläche und ein Aufnahmeloch aufweist, wobei die zwei Seiten des Hauptkörpers jeweils mit einem Durchgangsloch versehen sind, wobei die Durchgangslöcher mit dem Aufnahmeloch durchgängig verbunden sind; eine Desinfektionslampe, die auf der zweiten Oberfläche des Hauptkörpers angeordnet ist und eine Lichtemissionseinheit, eine Erfassungseinheit, eine Steuereinheit und eine Stromversorgungseinheit umfasst; und ein Befestigungsteil, das durch die Durchgangslöcher und das Aufnahmeloch des Hauptkörpers hindurchgeführt ist.
IMPROVEMENTS RELATED TO PARTICLE, INCLUDING SARS-CoV-2, DETECTION AND METHODS THEREFOR - - link
DEEP LEARNING BASED SYSTEM FOR DETECTION OF COVID-19 DISEASE OF PATIENT AT INFECTION RISK - The present invention relates to Deep learning based system for detection of covid-19 disease of patient at infection risk. The objective of the present invention is to solve the problems in the prior art related to technologies of detection of covid-19 disease using CT scan image processing. - link